Evidence-based estimate of appropriate radiotherapy utilization rate for prostate cancer (Q35035120)

5 August 2017

title

Evidence-based estimate of appropriate radiotherapy utilization rate for prostate cancer (English)

1 reference

5 August 2017

1 reference

Farshad Foroudi

1

1 reference

5 August 2017

Scott Tyldesley

2

1 reference

5 August 2017

Lisa Barbera

3

1 reference

5 August 2017

Jenny Huang

4

1 reference

5 August 2017

William J Mackillop

5

1 reference

5 August 2017

language of work or name

English

0 references

publication date

1 January 2003

1 reference

International Journal of Radiation Oncology Biology Physics

5 August 2017

published in

1 reference

5 August 2017

volume

55

1 reference

5 August 2017

issue

1

1 reference

5 August 2017

page(s)

51-63

1 reference

Radiotherapy in Sweden--a study of present use in relation to the literature and an estimate of future trends

5 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2802%2903866-X

7 January 2021

Does a centralized radiotherapy system provide adequate access to care?

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2802%2903866-X

7 January 2021

Variations in the management and outcome of non-small cell lung cancer in Ontario

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2802%2903866-X

7 January 2021

How do we bring an acceptable level of radiotherapy services to a dispersed population?

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2802%2903866-X

7 January 2021

Resources and productivity in radiation oncology in Denmark, Finland, Iceland, Norway and Sweden during 1987.

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2802%2903866-X

7 January 2021

Estimating the need for radiotherapy for lung cancer: an evidence-based, epidemiologic approach

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2802%2903866-X

7 January 2021

An evidence-based estimate of appropriate radiotherapy utilization rate for breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2802%2903866-X

7 January 2021

Limitations of epidemiologically based needs assessment. The case of prostatectomy

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2802%2903866-X

7 January 2021

Declining rates of extracapsular extension after radical prostatectomy: evidence for continued stage migration

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2802%2903866-X

7 January 2021

Detection of Organ-Confined Prostate Cancer Is Increased Through Prostate-Specific Antigen—Based Screening

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2802%2903866-X

7 January 2021

The Pathological Features and Prognosis of Prostate Cancer Detectable With Current Diagnostic Tests

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2802%2903866-X

7 January 2021

The national survey of prostate cancer in the United States by the American College of Surgeons

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2802%2903866-X

7 January 2021

The results of a five-year early prostate cancer detection intervention. Investigators of the American Cancer Society National Prostate Cancer Detection Project

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2802%2903866-X

7 January 2021

Rules of evidence and clinical recommendations on the use of antithrombotic agents

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2802%2903866-X

7 January 2021

Generalizability of the surveillance, epidemiology, and end results registry population: factors relevant to epidemiologic and health care research

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2802%2903866-X

7 January 2021

The National Cancer Data Base report on lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2802%2903866-X

7 January 2021

Does the completeness of prostate sampling predict outcome for patients undergoing radical prostatectomy?: data from the CAPSURE database

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2802%2903866-X

7 January 2021

Optimizing patient selection for dose escalation techniques using the prostate-specific antigen level, biopsy gleason score, and clinical T-stage

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2802%2903866-X

7 January 2021

Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2802%2903866-X

7 January 2021

Population-based study of long-term survival in patients with clinically localised prostate cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2802%2903866-X

7 January 2021

A needs-based methodology for allocating health care resources in Ontario, Canada: development and an application

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2802%2903866-X

7 January 2021

The National Cancer Data Base report on prostate carcinoma after the peak in incidence rates in the U.S. The American College of Surgeons Commission on Cancer and the American Cancer Society

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2802%2903866-X

7 January 2021

Results of conservative management of clinically localized prostate cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2802%2903866-X

7 January 2021

Seminal vesicle biopsy and laparoscopic pelvic lymph node dissection: Implications for patient selection in the radiotherapeutic management of prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2802%2903866-X

7 January 2021

Positive surgical margins at radical prostatectomy: importance of the apical dissection.

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2802%2903866-X

7 January 2021

Bilateral orchiectomy with or without flutamide for metastatic prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2802%2903866-X

7 January 2021

Immediate versus deferred treatment for advanced prostatic cancer: initial results of the Medical Research Council trial

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2802%2903866-X

7 January 2021

Performance status and comorbidity in elderly cancer patients compared with young patients with neoplasia and elderly patients without neoplastic conditions

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2802%2903866-X

7 January 2021

Treatment of advanced localised prostatic cancer by orchiectomy, radiotherapy, or combined treatment. A Medical Research Council Study. Urological Cancer Working Party--Subgroup on Prostatic Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2802%2903866-X

7 January 2021

The association between socioeconomic status, health insurance coverage, and quality of life in men with prostate cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2802%2903866-X

7 January 2021

Nodal involvement as a prognostic indicator in patients with prostatic carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2802%2903866-X

7 January 2021

Radical prostatectomy for adenocarcinoma of the prostate: the influence of preoperative and pathologic findings on biochemical disease-free outcome

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2802%2903866-X

7 January 2021

Hazard rates for progression after radical prostatectomy for clinically localized prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2802%2903866-X

7 January 2021

The National Cancer Data Base report on race, age, and region variations in prostate cancer treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2802%2903866-X

7 January 2021

10.1016/S0360-3016(02)03866-X

Identifiers

DOI

1 reference

5 August 2017

1 reference